Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 213 of the 213 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: The objective is to formulate clinical practice guidelines for treating Cushing's syndrome. PARTICIPANTS: Participants include an Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer. The European Society for Endocrinology co-sponsored the guideline. EVIDENCE: The Task Force used the Grading of Recommendations, Assessment, Development, and Evaluation system to describe the strength of recommendations and the quality of evidence. The Task Force commissioned three systematic reviews and used the best available evidence from other published systematic reviews and individual studies. CONSENSUS PROCESS: The Task Force achieved consensus through one group meeting, several conference calls, and numerous e-mail communications. Committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines. CONCLUSIONS: Treatment of Cushing's syndrome is essential to reduce mortality and associated comorbidities. Effective treatment includes the normalization of cortisol levels or action. It also includes the normalization of comorbidities via directly treating the cause of Cushing's syndrome and by adjunctive treatments (eg, antihypertensives). Surgical resection of the causal lesion(s) is generally the first-line approach. The choice of second-line treatments, including medication, bilateral adrenalectomy, and radiation therapy (for corticotrope tumors), must be individualized to each patient.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The guidelines provide a general definition of remission after resection of an ACTH-producing corticotroph tumor as morning serum cortisol levels <5 μg/dL (<138 nmol/L) or UFC <28-56 nmol/d (<10-20 μg/d) within 7 days of tumor resection (37).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [37]
In the citing paper
“Steroidogenesis inhibitors work by inhibiting one or more enzymes involved in steroidogenesis, decreasing cortisol and other steroid hormone production (37, 38).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [37]
In the citing paper
“Available medical therapies currently used in clinical practice to treat CS include medications from 3 classes: pituitary-directed therapies (for pituitary CD only), steroidogenesis inhibitors, and glucocorticoid receptor antagonists (37).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [37]
In the citing paper
“In patients with CS, surgical resection of the causative lesion(s) is the first-line treatment option regardless of etiology.”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [37]
In the citing paper
“Pituitary-directed therapies, including pasireotide (US/EU/Canada) and cabergoline (off-label use only), inhibit pituitary ACTH production and, in some cases, ectopic ACTH secretion from neuroendocrine tumors, thereby reducing downstream cortisol secretion (37, 128).”
From Measuring cortisol in Cushing syndrome: diagnosis, monitoring, and cortisol circadian rhythm improvement. (2026) · cites this paper as [37]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718 · cited 2×
“(17) 2810 Nieman et al Guidelines on Cushing’s Syndrome Treatment J Clin Endocrinol Metab, August 2015, 100(8):2807–2831”
BackgroundSelf-citationKahn (2012) · doi:10.1378/chest.11-2296 · Cited by 2,693
Self-citationPrevention of VTE in Nonorthopedic Surgical Patients
Gould, M. K., Garcia, D. A., Wren, S. M., Karanicolas, P. J., Arcelus, J. I., Heit, J. A., & Samama, C. M. (2012) · Chest · doi:10.1378/chest.11-2297 · Cited by 2,131
Lacroix, A., Feelders, R. A., Stratakis, C. A., & Nieman, L. K. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61375-1 · Cited by 1,777
Self-citationMolitch, M. E., Clemmons, D. R., Malozowski, S., Merriam, G. R., & Vance, M. L. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-0179 · Cited by 1,047
Cushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851
Starkman, M. N., Gebarski, S. S., Berent, S., & Schteingart, D. E. (1992) · Biological Psychiatry · doi:10.1016/0006-3223(92)90079-f · Cited by 840
The natural history of cushing's syndrome
Plotz, C. M., Knowlton, A. I., & Ragan, C. (1952) · The American Journal of Medicine · doi:10.1016/0002-9343(52)90027-2 · Cited by 763
Cited by
Items 401–500 of 1,000
InSH Consensus Guideline for the Management of Hypertension, 2023
Gupta, R., Maheshwari, A., Verma, N., Narasingan, S. N., & Tripathi, K. (2023) · Hypertension Journal · doi:10.61081/htnj/23v9i302 · Cited by 16
Fatty Liver Disease Along Cushing Syndrome Evolution
Marengo, M., Briet, C., Munier, M., Boursier, J., Rodien, P., & Suteau, V. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae568 · Cited by 16
Prospective study of metyrapone in endogenous Cushing's syndrome (PROMPT)
Nieman, L. K., Boscaro, M., Scaroni, C. M., Deutschbein, T., Mezősi, E., Driessens, N., Georgescu, C. E., Motyka, M., Hubalewska–Dydejczyk, A., Jarząb, B., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf181 · Cited by 16
Self-citationBianchi, L., Campi, B., Sessa, M. R., Marco, G. D., Ferrarini, E., Zucchi, R., Marcocci, C., Vitti, P., Manetti, L., Saba, A., et al. (2019) · Journal of Endocrinological Investigation · doi:10.1007/s40618-019-01050-5 · Cited by 16
Updates in the outcomes of radiation therapy for Cushing’s disease
Gheorghiu, M. L. (2021) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2021.101514 · Cited by 16
Metyrapone in Cushing’s syndrome: a profile of its use
Al-Salama, Z. T. (2021) · Drugs & Therapy Perspectives · doi:10.1007/s40267-021-00853-y · Cited by 16
Old Problem, New Concerns: Hypercortisolemia in the Time of COVID-19
Berlińska, A., Świątkowska−Stodulska, R., & Sworczak, K. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.711612 · Cited by 16
Seastedt, K. P., Alyateem, G., Pittala, K., Steinberg, S. M., Schrump, D. S., Nieman, L. K., & Hoang, C. D. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.24739 · Cited by 16
Self-citationThe hypothalamic-pituitary-gonad axis in male Cushing’s disease before and after curative surgery
Zheng, H., Wang, Q., Cui, Q., Sun, Q., Wu, W., Ji, L., He, M., Lü, B., Zhang, Z., Ma, Z., et al. (2022) · Endocrine · doi:10.1007/s12020-022-03083-y · Cited by 16
Is the Adrenal Incidentaloma Functionally Active? An Approach-To-The-Patient-Based Review
Bernardi, S., Calabrò, V., Cavallaro, M., Lovriha, S., Eramo, R., Fabris, B., de Manzini, N., & Dobrinja, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11144064 · Cited by 16
Pituitary surgery in Cushing’s disease: first line treatment and role of reoperation
Jones, P. S., & Swearingen, B. (2022) · Pituitary · doi:10.1007/s11102-022-01254-8 · Cited by 16
Najafabadi, A. H. Z., van der Meulen, M., Zurita, A. L. P., Ahmed, S. F., van Furth, W. R., Charmandari, E., Hiort, O., Pereira, A. M., Dattani, M., Vitali, D., et al. (2022) · Endocrine Connections · doi:10.1530/ec-22-0349 · Cited by 16
Peixe, C. R., Alexandre, M. I., Gomes, A. C., Nobre, E. L., Silva, A. L., Oliveira, T., Lopéz‐Presa, D., Faria, C. C., Miguéns, J., Bugalho, M. J., et al. (2023) · Pituitary · doi:10.1007/s11102-023-01319-2 · Cited by 16
An Ectopic ACTH Secreting Metastatic Parotid Tumour
Dacruz, T., Kalhan, A., Rashid, M., & Obuobie, K. (2016) · Case Reports in Endocrinology · doi:10.1155/2016/4852907 · Cited by 16
Ectopic Adrenocorticotropic Hormone–Secreting Pituitary Adenomas: An Underestimated Entity
Knappe, U. J., Jaspers, C., Buschsieweke, D., Reinbold, W., Al-Omari, A., Saeger, W., Ehlenz, K., Mann, W. A., Kann, P. H., & Feldkamp, J. (2017) · Neurosurgery · doi:10.1227/neu.0000000000001319 · Cited by 16
Chan, C., & Roberts, J. M. (2017) · BMJ Case Reports · doi:10.1136/bcr-2017-221580 · Cited by 16
Effects of Ketoconazole on ACTH-Producing and Non-ACTH-Producing Neuroendocrine Tumor Cells
Herrera-Martínez, A. D., Feelders, R. A., de Herder, W. W., Castano, J. P., Moreno, M. Á. G., Dogan, F., van den Dungen, R., van Koetsveld, P. M., & Hofland, L. J. (2019) · Hormones and Cancer · doi:10.1007/s12672-019-00361-6 · Cited by 16
Medical Management of Cushing Disease
Tritos, N. A., & Biller, B. M. K. (2019) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2019.05.007 · Cited by 16
Self-citationHypokalemia associated with mifepristone use in the treatment of Cushing’s syndrome
Sai, K., Lal, A., Maradana, J. L., Velamala, P. R., & Nitin, T. (2019) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-19-0064 · Cited by 16
Cui, Q., Liu, X., Sun, Q., Sun, W., Zheng, H., He, M., Zhang, Z., Ma, Z., Shen, M., Shou, X., et al. (2023) · Endocrine · doi:10.1007/s12020-023-03405-8 · Cited by 15
Sleep disruption in patients with active and treated endogenous Cushing’s syndrome
Geer, E. B., Grillo, I., Li, Q., Robins, H., Cohen, V. V., Baratz, H. Q., Garcia, C., Sazo, M., Lin, A. L., Cohen, M. A., et al. (2024) · Pituitary · doi:10.1007/s11102-024-01450-8 · Cited by 15
Działach, Ł., Sobolewska, J., Respondek, W., Wojciechowska-Luźniak, A., Kuca, P., & Witek, P. (2024) · Endocrine · doi:10.1007/s12020-024-04135-1 · Cited by 15
Purnomo, A. F., Daryanto, B., & Nurhadi, P. (2021) · Medical Archives · doi:10.5455/medarh.2021.75.431-435 · Cited by 15
Varricchio, L., Geer, E. B., Martelli, F., Mazzarini, M., Funnell, A. P. W., Bieker, J. J., Papayannopoulou, T., & Migliaccio, A. R. (2022) · Haematologica · doi:10.3324/haematol.2021.280542 · Cited by 15
Recommendations for the diagnosis and radiological follow-up of pituitary neuroendocrine tumours
Fajardo, C., Villar, R., Gómez‐Ansón, B., Brea, B., Mosqueira, A. J., Mollá, E., Enseñat, J., Riesgo, P., Arboniés, J. C., & Hernando, O. (2022) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2021.10.014 · Cited by 15
Xiao, L., Ouyang, T., Wu, B., Xie, S., Tang, B., He, Y., Ding, H., Wu, X., & Hong, T. (2022) · Neurosurgery · doi:10.1227/neu.0000000000002197 · Cited by 15
Liu, Z., Hou, B., You, H., Lü, L., Duan, L., Li, M. L., Deng, K., Yao, Y., Zhu, H., & Feng, F. (2023) · European Radiology · doi:10.1007/s00330-023-09585-1 · Cited by 15
Blew, K., Mater, D. V., & PAGE, L. C. (2023) · JCEM Case Reports · doi:10.1210/jcemcr/luad101 · Cited by 15
Paediatric Cushing’s disease: long-term outcome and predictors of recurrence
Savage, M. O., & Ferrigno, R. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1345174 · Cited by 15
Self-citationMarques, P., Barry, S., Ronaldson, A., Ogilvie, A., Storr, H. L., Goadsby, P. J., Powell, M. P., Dang, M. N., Chahal, H., Evanson, J., et al. (2018) · International Journal of Endocrinology · doi:10.1155/2018/8581626 · Cited by 15
Machado, M. C., Fragoso, M. C. B. V., Moreira, A. C., Boguszewski, C. L., Vieira, L., Naves, L. A., Vilar, L., de Araújo, L. A., Musolino, N. R. D. C., Miranda, P. A. C., et al. (2018) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000014 · Cited by 15
Secretory tumors of the pituitary gland: a clinical biochemistry perspective
Gounden, V., Rampursat, Y., & Jialal, I. (2018) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2018-0552 · Cited by 15
Barbot, M., Regazzo, D., Mondin, A., Zilio, M., Lizzul, L., Zaninotto, M., Plebani, M., Arnaldi, G., Ceccato, F., & Scaroni, C. M. (2020) · Pituitary · doi:10.1007/s11102-020-01055-x · Cited by 15
Dutta, A., Gupta, N., Walia, R., Bhansali, A. K., Dutta, P. R., Bhadada, S. K., Pivonello, R., Ahuja, C. K., Dhandapani, S., Hajela, A., et al. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01495-z · Cited by 15
Tumor Shrinkage by Metyrapone in Cushing Disease Exhibiting Glucocorticoid-Induced Positive Feedback
Tsujimoto, Y., Shichi, H., Fukuoka, H., Yamamoto, M., Sato, I., Imanishi, T., Nakamura, T., Inoshita, N., Ishida, A., Yamada, S., et al. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab055 · Cited by 15
Radvany, M. G., Quiñones‐Hinojosa, A., Gallia, G. L., Wand, G. S., & Salvatori, R. (2016) · Endocrine Practice · doi:10.4158/ep161266.or · Cited by 15
Mehta, G. U., Ding, D., Gupta, A., Kano, H., Sisterson, N. D., Martínez-Moreno, N., Kršek, M., Yang, H., Lee, C., Liščák, R., et al. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-2817-5 · Cited by 15
Current strategies for the treatment of severe Cushing’s syndrome
Alexandraki, K., & Grossman, A. B. (2015) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2016.1123615 · Cited by 14
Fano, M. D., Falorni, A., Malara, M., Porcellati, F., & Fanelli, C. G. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s466328 · Cited by 14
Oberman, D. Z., Sanchez-Garavito, E. J., Perez‐Vega, C., Donaldson, A. M., Olomu, O. U., Graepel, S. P., Edgar, M. A., Quiñones‐Hinojosa, A., Chaichana, K. L., Samson, S. L., et al. (2025) · Pituitary · doi:10.1007/s11102-024-01476-y · Cited by 14
Adrenal incidentaloma: differential diagnosis and management strategies
Morelli, V., & Palmieri, S. (2018) · Minerva Endocrinology · doi:10.23736/s0391-1977.18.02868-7 · Cited by 14
Thromboembolic disease in hypercortisolism
Capatina, C. A.-M., & Fleseriu, M. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000630 · Cited by 14
Fajardo, C., Villar, R., Gómez‐Ansón, B., Brea, B., Mosqueira, A. J., Mollá, E., Enseñat, J., Riesgo, P., Arboniés, J. C., & Hernando, O. (2021) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2021.10.005 · Cited by 14
Treatment of Primary Pigmented Nodular Adrenocortical Disease
Gang, X., Wang, G., Liu, X., Zhang, S., & Guo, Y. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1948-6990 · Cited by 14
Lu, D., Yu, N., Ma, X., Zhang, J., & Guo, X. (2018) · Medicine · doi:10.1097/md.0000000000013322 · Cited by 14
Prognostic usefulness of ACTH in the postoperative period of Cushing’s disease
Galiana, P. A., Fajardo, C., Riesgo-Suárez, P., Pérez-Bermejo, M., Ríos-Pérez, C., & Gómez-Vela, J. (2019) · Endocrine Connections · doi:10.1530/ec-19-0297 · Cited by 14
Cushing's disease—from Minnie G to key issues in the early 21st century
Kelsall, A., & Newell-Price, J. D. C. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30343-2 · Cited by 14
Self-citationMallari, R. J., Thakur, J. D., Barkhoudarian, G., Eisenberg, A., Rodriguez, A., Rettinger, S. R., Cohan, P., Nieman, L. K., & Kelly, D. F. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab659 · Cited by 14
Self-citationNewell-Price, J. D. C. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.118 · Cited by 14
Self-citationLin, W., Huang, H., Wen, J., Wang, N., Wang, S.-Y., Wang, C., & Chen, G. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.07.94 · Cited by 14
Fan, Y., Li, D., Liu, Y., Feng, M., Chen, Q., & Wang, R. (2020) · International Journal of Machine Learning and Cybernetics · doi:10.1007/s13042-020-01192-6 · Cited by 14
Insights on epidemiology, morbidity and mortality of Cushing’s disease in Northern Ireland
Loughrey, P. B., Herron, B. M., Cooke, S., Weir, P., Smyth, J., Mullan, K., Healy, E. G., Evanson, J., Craig, S. G., James, J. A., et al. (2024) · Endocrine Related Cancer · doi:10.1530/erc-24-0028 · Cited by 13
Oral Corticosteroids for Skin Disease in the Older Population: Minimizing Potential Adverse Effects
Sparling, K., & Butler, D. C. (2024) · Drugs & Aging · doi:10.1007/s40266-024-01143-8 · Cited by 13
Yokoyama, K., Matsuki, M., Isozaki, T., Ito, K., Imokawa, T., Ozawa, A., Kimura, K., Tsuchiya, J., & Tateishi, U. (2025) · Japanese Journal of Radiology · doi:10.1007/s11604-025-01732-6 · Cited by 13
Medical management pathways for Cushing’s disease in pituitary tumors centers of excellence (PTCOEs)
Giustina, A., Uygur, M. M., Frara, S., Barkan, A. L., Biermasz, N. R., Chanson, P., Freda, P. U., Gadelha, M. R., Haberbosch, L., Kaiser, U. B., et al. (2025) · Pituitary · doi:10.1007/s11102-024-01485-x · Cited by 13
Update on Medical Treatment of Cushing’s Syndrome
Dillon, B. R., Agrawal, N., Schwarz, Y., Dancel-Manning, K., Tabarin, A., Lacroix, A., Hofland, L. J., & Feelders, R. A. (2025) · Drugs · doi:10.1007/s40265-025-02223-8 · Cited by 13
Self-citationZhuang, Z., Liu, X., Bao, X., Pan, B., Deng, K., Yao, Y., Lian, W., Xing, B., Zhu, H., Lü, L., et al. (2018) · Medicine · doi:10.1097/md.0000000000013148 · Cited by 13
Dai, C., Liang, S., Liu, X.-H., Fan, Y., Bao, X., Yao, Y., Deng, K., Lü, L., Wang, R., & Feng, M. (2020) · Endocrine Practice · doi:10.4158/ep-2020-0177 · Cited by 13
Spontaneous remission of Cushing's disease: A systematic review
Ilie, I. R. P., Herdean, A. M., Herdean, A. I., & Georgescu, C. E. (2021) · Annales d Endocrinologie · doi:10.1016/j.ando.2021.10.002 · Cited by 13
Abbas, A., Schini, M., Ainsworth, G., Brown, S., Oughton, J. B., Crowley, R. K., Cooper, M. S., Fairclough, R. J., Eastell, R., & Stewart, P. M. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac100 · Cited by 13
Altered hippocampal volume and functional connectivity in patients with Cushing's disease
Li, C., Zhang, Y., Wang, W., Zhou, T., Yu, X., & Tao, H. (2022) · Brain and Behavior · doi:10.1002/brb3.2507 · Cited by 13
Trimpou, P., Backlund, E., Ragnarsson, Ó., Skoglund, T. S., Hallén, T., Gudnadottir, G., Carlqvist, J., & Farahmand, D. (2022) · World Neurosurgery · doi:10.1016/j.wneu.2022.07.027 · Cited by 13
de Almeida, T. S., Rodrigues, T. D. C., Costenaro, F., Scaffaro, L. A., Farenzena, M., Gastaldo, F., & Czepielewski, M. A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1224001 · Cited by 13
Ceccato, F., Boccato, M., Zilio, M., Barbot, M., Frigo, A. C., Luisetto, G., Boscaro, M., Scaroni, C. M., & Camozzi, V. (2017) · Hormone and Metabolic Research · doi:10.1055/s-0043-115008 · Cited by 13
Long-term outcome in patients after treatment for Cushing’s disease in childhood
Pasternak-Pietrzak, K., Moszczyńska, E., Roszkowski, M., Kot, K., Marczak, E., Grajkowska, W., Pronicki, M., & Szalecki, M. (2019) · PLoS ONE · doi:10.1371/journal.pone.0226033 · Cited by 13
Pasternak-Pietrzak, K., Moszczyńska, E., Jurkiewicz, E., & Szalecki, M. (2020) · Endokrynologia Polska · doi:10.5603/ep.a2019.0040 · Cited by 13
Cristante, J., Lepelley, M., Mallaret, M., Carreau, A., & Chabre, O. (2020) · Annales d Endocrinologie · doi:10.1016/j.ando.2020.11.002 · Cited by 13
Akirov, A., Larouche, V., Shimon, I., Asa, S. L., Mete, Ö., Sawka, A. M., Gentili, F., & Ezzat, S. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.620005 · Cited by 13
Chen, Z., Jia, Q., Zhao, Z., Zhang, Q., Chen, Y., Qiao, N., Ye, Z., Ji, C., Zhang, Y., He, W., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac280 · Cited by 13
Wexler, T., & Page‐Wilson, G. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15660 · Cited by 13
New Insights in Cushing Disease Treatment With Focus on a Derivative of Vitamin A
Fuertes, M., Tkatch, J., Rosmino, J., Nieto, L., Guitelman, M. A., & ARZT, E. S. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00262 · Cited by 13
Cabergoline in severe ectopic or occult Cushing’s syndrome
Ilie, M. D., Raverot, V., Tronc, F., Vasiljevic, A., Borson‐Chazot, F., & Raverot, G. (2019) · European Journal of Endocrinology · doi:10.1530/eje-18-1014 · Cited by 13
Challenges in the postsurgical recovery of cushing syndrome: glucocorticoid withdrawal syndrome
Zhang, C. D., & Ioachimescu, A. G. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1353543 · Cited by 13
Corticotroph hyperplasia and Cushing disease: diagnostic features and surgical management
Catalino, M. P., Meredith, D. M., Girolami, U. D., Tavakol, S., Min, L., & Laws, E. R. (2020) · Journal of neurosurgery · doi:10.3171/2020.5.jns201514 · Cited by 12
Functioning neuroendocrine tumors (NET): Minimum requirements for a NET specialist
Spada, F., Rossi, R. E., Modica, R., Gelsomino, F., Rinzivillo, M., Rubino, M., Pisa, E., Salvia, A. L., & Fazio, N. (2025) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2025.102907 · Cited by 12
Role of “old” pharmacological agents in the treatment of Cushing’s syndrome
Ambrogio, A. G., & Cavagnini, F. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0462-4 · Cited by 12
Case report of a bilateral adrenal myelolipoma associated with Cushing disease
Park, S. Y., Kwak, M. K., Kim, H. J., Park, H. K., Suh, K., Yoo, M. H., Jin, S. Y., Yun, S., & Byun, D. W. (2017) · Medicine · doi:10.1097/md.0000000000009455 · Cited by 12
Approach to patients with bilateral adrenal incidentalomas
Vassiliadi, D. A., Partsalaki, E., & Tsagarakis, S. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000536 · Cited by 12
Abdali, A., Kalinin, P. L., Trunin, Y. Y., Astaf’Eva, L. E., Shkarubo, A. N., Chmutin, G. E., Chavda, V. K., Голанов, А. В., Abdali, B., Chernov, I. V., et al. (2021) · British Journal of Neurosurgery · doi:10.1080/02688697.2021.1921107 · Cited by 12
Cui, M., Zhou, T., Feng, S., Liu, X., Wang, F., Zhang, Y., & Yu, X. (2021) · NeuroImage Clinical · doi:10.1016/j.nicl.2021.102770 · Cited by 12
Bosman, A., van den Beld, A. W., Feelders, R. A., & Zillikens, M. C. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.733793 · Cited by 12
Draft of the clinical practice guidelines “Adrenal incidentaloma”
Beltsevich, D. G., Troshina, E. A., Mel'nichenko, G. A., Platonova, N. M., Ladygina, D. O., & Chevais, A. (2021) · Endocrine Surgery · doi:10.14341/serg12712 · Cited by 12
Osilodrostat — an emerging drug for the medical management of Cushing’s disease
Witek, P., Mehlich, A., Stasiewicz, A., Jawiarczyk-Przybyłowska, A., & Bolanowski, M. (2022) · Endokrynologia Polska · doi:10.5603/ep.a2022.0009 · Cited by 12
Doğanşen, S. Ç., Soyluk, Ö., Selek, A., Erol, S., Hekimsoy, Z., Esen, A. D., Dursun, H., Şahin, S., Örük, G., Mert, M., et al. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1783-7901 · Cited by 12
Case Report of Cushing's Syndrome with an Acute Psychotic Presentation.
Wu, Y., Chen, J., Ma, Y., & Chen, Z. (2016) · PubMed Central · doi:10.11919/j.issn.1002-0829.215126 · Cited by 12
Osilodrostat for the treatment of Cushing’s disease
Rasool, S., & Skinner, B. W. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1897106 · Cited by 12
Diagnosis and differential diagnosis of adrenal incidentalomas
Молашенко, Н. В., Platonova, N. M., Beltsevich, D. G., Yukina, M. Y., & Troshina, E. A. (2016) · Obesity and metabolism · doi:10.14341/omet2016439-44 · Cited by 12
Geer, E. B., Ayala, A., Bonert, V., Carmichael, J. D., Gordon, M. B., Katznelson, L., Manuylova, E., Shafiq, I., Surampudi, V., Swerdloff, R. S., et al. (2017) · Pituitary · doi:10.1007/s11102-017-0801-2 · Cited by 11
Self-citationPostoperative serum cortisol and Cushing disease recurrence in patients with corticotroph adenomas
Catalino, M. P., Moore, D. T., Ironside, N., Munoz, A. R., Coley, J., Jonas, R., Kearns, K., Min, L., Vance, M. L., Jane, J. A., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad347 · Cited by 11
Real-World Osilodrostat Effectiveness and Safety in Nonpituitary Cushing Syndrome
Tabarin, A., Bertherat, J. Y., Decoudier, B., Lasolle, H., Lefèbvre, H., Drui, D., Vaillant, C., Morera, J., Castinetti, F., Cristante, J., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf633 · Cited by 11
Self-citationGao, L., Liu, L., Shi, L., Luo, Y., Wang, Z., Guo, X., & Xing, B. (2020) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-020-09540-1 · Cited by 11
Efficacy and Safety of Stereotactic Radiotherapy in Cushing’s Disease: A Single Center Experience
Apaydın, T., Özkaya, H. M., Durmaz, S. M., Meral, R., & Kadıoğlu, P. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1217-7365 · Cited by 11
Jiménez-Canizales, C. E., Rojas, W., Alonso, D., Romero, I., Rodríguez, S. C. T., Veronesi, L. A., Modica, R., & Colao, A. A. L. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02080-w · Cited by 11
Sulu, C., Koca, O., Icli, T. B., Öz, A., Kargın, O. A., Durcan, E., Şahin, S., Arslan, S., Turan, Ş., Kadıoğlu, P., et al. (2023) · Neuroradiology · doi:10.1007/s00234-023-03156-3 · Cited by 11
An, X., Chen, T., Mo, D., Shen, S., Zhang, D., Zhang, T., Tian, H., Li, Y., Li, J., Li, L., et al. (2023) · Endocrine · doi:10.1007/s12020-023-03395-7 · Cited by 11
Pituitary adenomas registry in Thailand
Kwancharoen, R., Deerochanawong, C., Peerapatdit, T., & Salvatori, R. (2023) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2023.07.026 · Cited by 11
Medical treatment of functional pituitary adenomas, trials and tribulations
Capatina, C. A.-M., Hanzu, F. A., Hinojosa‐Amaya, J. M., & Fleseriu, M. (2024) · Journal of Neuro-Oncology · doi:10.1007/s11060-024-04670-x · Cited by 11
Colao, A., Scaroni, C. M., Mezősi, E., Saiegh, L., Puig‐Domingo, M., Marques, P., & Deutschbein, T. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae073 · Cited by 11
Growth hormone deficiency in adults with Cushing's disease
Tritos, N. A. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101474 · Cited by 11
Chen, K., Chen, S., Lü, L., Zhu, H., Zhang, X., Tong, A., Pan, H., Wang, R., & Lu, Z. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.720823 · Cited by 11
Metadata
- Authors
- Nieman, L. K., Biller, B. M. K., Findling, J. W., Murad, M. H., Newell-Price, J., Savage, M. O., & Tabarin, A.
- Affiliations
- National Institutes of Health (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2015-08
- Volume
- 100
- Issue
- 8
- Pages
- 2807-2831
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC4525003
- OpenAlex
- W2127952551
- Semantic Scholar
- 4d26bfff9a2f2ea132ea661d03d84dc8b2293884
- Cited by
- 1,270
- References
- 213
- Citations by year
- 2026: 99 · 2025: 120 · 2024: 104 · 2023: 117 · 2022: 148 · 2021: 169 · 2020: 116 · 2019: 112 · 2018: 116 · 2017: 83 · 2016: 75 · 2015: 6
- FWCI
- 80.93
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Oncology › Neuroendocrine Tumor Research Advances
- Keywords
- Cushing's syndrome, hypercortisolism, surgical resection, bilateral adrenalectomy, radiotherapy, corticotropinoma, comorbidity management, treatment selection
- MeSH terms
- Adrenal Gland Neoplasms, Adrenalectomy, Cushing Syndrome, Endocrinology, Humans, Patient Care Planning, Pituitary Neoplasms, Recurrence, Remission Induction, Evidence-Based Medicine, Consensus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.